Abstract
Intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized, and are now the mainstay of treatment for neovascular age-related macular degeneration (AMD) [1], [2], [3].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
